Michael D. Kalos
Impact in
- Oncology top 0.05%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Immunology top 0.1%
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
Papers in
- Oncology 84
- CAR-T cell therapy research 73
- Cancer Immunotherapy and Biomarkers 16
- Immunology 53
- Immunotherapy and Immune Responses 29
- Immune Cell Function and Interaction 19
- Co-authors
- Carl H. June (29 shared papers)Bruce L. Levine (19 shared papers)David L. Porter (14 shared papers)Adam Bagg (3 shared papers)Stephan A. Grupp (18 shared papers)Anne Chew (8 shared papers)Sharyn I. Katz (1 shared paper)David Maxwell Barrett (5 shared papers)
- Journals
- Blood (22 papers)Clinical Cancer Research (7 papers)Journal for ImmunoTherapy of Cancer (6 papers)Cancer Immunology Research (6 papers)Science Translational Medicine (5 papers)
- Partner nations
- United StatesNetherlandsSwitzerland
In The Last Decade
Michael D. Kalos
115 papers receiving 21.8k citations
Michael D. Kalos's Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 16.4k
- Immunology 8.4k
- Genetics 5.1k
- Virology 659
- Hematology 1.3k
Countries citing papers authored by Michael D. Kalos
This map shows the geographic impact of Michael D. Kalos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Kalos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Kalos more than expected).
Fields of papers citing papers by Michael D. Kalos
This network shows the impact of papers produced by Michael D. Kalos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Kalos. The network helps show where Michael D. Kalos may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael D. Kalos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 117 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia Hit paper breakdown → | 2011 | 3013 |
| 2 | Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia Hit paper breakdown → | 2013 | 2979 |
| 3 | T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia Hit paper breakdown → | 2011 | 2026 |
| 4 | Gene Editing of CCR5 in Autologous CD4 T Cells of Persons Infected with HIV Hit paper breakdown → | 2014 | 1105 |
| 5 | Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma Hit paper breakdown → | 2013 | 978 |
| 6 | Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies Hit paper breakdown → | 2013 | 769 |
| 7 | Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells Hit paper breakdown → | 2018 | 736 |
| 8 | NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma Hit paper breakdown → | 2015 | 725 |
| 9 | Identification of a Titin-Derived HLA-A1–Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3–Directed T Cells Hit paper breakdown → | 2013 | 579 |
| 10 | Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells Hit paper breakdown → | 2012 | 556 |
| 11 | Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy Hit paper breakdown → | 2013 | 545 |
| 12 | T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans Hit paper breakdown → | 2013 | 521 |
| 13 | Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies Hit paper breakdown → | 2016 | 498 |
| 14 | 2010 | 458 | |
| 15 | 2014 | 415 | |
| 16 | 2013 | 400 | |
| 17 | The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade Hit paper breakdown → | 2018 | 365 |
| 18 | 2010 | 322 | |
| 19 | 2018 | 287 | |
| 20 | 2012 | 275 |
About Michael D. Kalos
Michael D. Kalos is a scholar working on Oncology, Immunology, Genetics, Genetics and Hematology, having authored 117 papers that have together received 22.5k indexed citations. Recurring topics across this work include CAR-T cell therapy research (73 papers), Immunotherapy and Immune Responses (29 papers), Immune Cell Function and Interaction (19 papers), Virus-based gene therapy research (18 papers), Cancer Immunotherapy and Biomarkers (16 papers), Viral Infectious Diseases and Gene Expression in Insects (8 papers), Chronic Lymphocytic Leukemia Research (8 papers) and Acute Lymphoblastic Leukemia research (8 papers). The work is most often cited by research in Oncology (16.4k citations), Immunology (8.4k citations), Genetics (5.1k citations), Virology (659 citations) and Hematology (1.3k citations). Michael D. Kalos has collaborated with scholars based in United States, Netherlands and Switzerland. Frequent co-authors include Carl H. June, Bruce L. Levine, David L. Porter, Adam Bagg, Stephan A. Grupp, Anne Chew, Sharyn I. Katz, David Maxwell Barrett, David T. Teachey and Susan R. Rheingold. Their work appears in journals such as Blood, Clinical Cancer Research, Journal for ImmunoTherapy of Cancer, Cancer Immunology Research and Science Translational Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.